Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
BCL3
Introduction
B-cell lymphoma 3-encoded protein is a protein that in humans is encoded by the BCL3 gene.[1][2]
This gene is a proto-oncogene candidate. It is identified by its translocation into the immunoglobulin alpha-locus in some cases of B-cell leukemia. The protein encoded by this gene contains seven ankyrin repeats, which are most closely related to those found in I kappa B proteins. This protein functions as a transcriptional coactivator that activates through its association with NF-kappa B homodimers. The expression of this gene can be induced by NF-kappa B, which forms a part of the autoregulatory loop that controls the nuclear residence of p50 NF-kappa B.[3]
Like BCL2, BCL5, BCL6, BCL7A, BCL9, and BCL10, it has clinical significance in lymphoma.
References
References
- ↑ Wulczyn FG, Naumann M, Scheidereit C (Sep 1992). “Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B”. Nature. 358 (6387): 597–9. doi:10.1038/358597a0. PMID 1501714.
- ↑ Ohno H, Takimoto G, McKeithan TW (May 1990). “The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control”. Cell. 60 (6): 991–7. doi:10.1016/0092-8674(90)90347-H. PMID 2180580.
- ↑ “Entrez Gene: BCL3 B-cell CLL/lymphoma 3”.
- ↑ 4.0 4.1 4.2 4.3 Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A (Jun 1999). “The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators”. Oncogene. 18 (22): 3316–23. doi:10.1038/sj.onc.1202717. PMID 10362352.
- ↑ 5.0 5.1 5.2 Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC, Lee JW (Oct 1999). “Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation”. J. Biol. Chem. 274 (40): 28491–6. doi:10.1074/jbc.274.40.28491. PMID 10497212.
- ↑ “Molecular Interaction Database”. Archived from the original on 2006-05-06. Retrieved 2012-05-08.
- ↑ 7.0 7.1 Thornburg NJ, Pathmanathan R, Raab-Traub N (Dec 2003). “Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma”. Cancer Res. 63 (23): 8293–301. PMID 14678988.
- ↑ Naumann M, Wulczyn FG, Scheidereit C (January 1993). “The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B”. EMBO J. 12 (1): 213–22. PMC 413194. PMID 8428580.
- ↑ Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C (Sep 1999). “NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes”. EMBO J. 18 (17): 4766–78. doi:10.1093/emboj/18.17.4766. PMC 1171549. PMID 10469655.
- ↑ Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (Mar 1993). “The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers”. Cell. 72 (5): 729–39. doi:10.1016/0092-8674(93)90401-b. PMID 8453667.
- ↑ Na SY, Choi HS, Kim JW, Na DS, Lee JW (Nov 1998). “Bcl3, an IkappaB protein, as a novel transcription coactivator of the retinoid X receptor”. J. Biol. Chem. 273 (47): 30933–8. doi:10.1074/jbc.273.47.30933. PMID 9812988.
Further reading
Further reading
- Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U (September 1992). “The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition”. Nature. 359 (6393): 339–42. doi:10.1038/359339a0. PMID 1406939.
- Bhatia K, Huppi K, McKeithan T, Siwarski D, Mushinski JF, Magrath I (September 1991). “Mouse bcl-3: cDNA structure, mapping and stage-dependent expression in B lymphocytes”. Oncogene. 6 (9): 1569–73. PMID 1923524.
- Mills FC, Brooker JS, Camerini-Otero RD (1991). “Sequences of human immunoglobulin switch regions: implications for recombination and transcription”. Nucleic Acids Res. 18 (24): 7305–16. doi:10.1093/nar/18.24.7305. PMC 332867. PMID 2124350.
- Crossen PE, Kennedy MA, Heaton DC, Morrison MJ (1993). “Cloning and sequencing of a t(14;19) breakpoint that involves the C mu switch region”. Genes Chromosomes Cancer. 8 (1): 60–2. doi:10.1002/gcc.2870080110. PMID 7691160.
- McKeithan TW, Ohno H, Dickstein J, Hume E (1995). “Genomic structure of the candidate proto-oncogene BCL3”. Genomics. 24 (1): 120–6. doi:10.1006/geno.1994.1588. PMID 7896265.
- Zhang Q, Didonato JA, Karin M, McKeithan TW (1994). “BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins”. Mol. Cell. Biol. 14 (6): 3915–26. PMC 358758. PMID 8196632.
- Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D (July 1993). “The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers”. Genes Dev. 7 (7B): 1354–63. doi:10.1101/gad.7.7b.1354. PMID 8330739.
- Naumann M, Wulczyn FG, Scheidereit C (1993). “The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B”. EMBO J. 12 (1): 213–22. PMC 413194. PMID 8428580.
- Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (March 1993). “The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers”. Cell. 72 (5): 729–39. doi:10.1016/0092-8674(93)90401-B. PMID 8453667.
- Nolan GP, Fujita T, Bhatia K, Huppi C, Liou HC, Scott ML, Baltimore D (June 1993). “The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner”. Mol. Cell. Biol. 13 (6): 3557–66. PMC 359825. PMID 8497270.
- Watanabe N, Iwamura T, Shinoda T, Fujita T (June 1997). “Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation”. EMBO J. 16 (12): 3609–20. doi:10.1093/emboj/16.12.3609. PMC 1169985. PMID 9218802.
- Bundy DL, McKeithan TW (1998). “Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA”. J. Biol. Chem. 272 (52): 33132–9. doi:10.1074/jbc.272.52.33132. PMID 9407099.
- Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM, Zimmerman GA (May 1998). “Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets”. Proc. Natl. Acad. Sci. U.S.A. 95 (10): 5556–61. doi:10.1073/pnas.95.10.5556. PMC 20416. PMID 9576921.
- Na SY, Choi HS, Kim JW, Na DS, Lee JW (November 1998). “Bcl3, an IkappaB protein, as a novel transcription coactivator of the retinoid X receptor”. J. Biol. Chem. 273 (47): 30933–8. doi:10.1074/jbc.273.47.30933. PMID 9812988.
- Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A (June 1999). “The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators”. Oncogene. 18 (22): 3316–23. doi:10.1038/sj.onc.1202717. PMID 10362352.
- Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC, Lee JW (October 1999). “Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation”. J. Biol. Chem. 274 (40): 28491–6. doi:10.1074/jbc.274.40.28491. PMID 10497212.
- Neumann M, Fries H, Scheicher C, Keikavoussi P, Kolb-Mäurer A, Bröcker E, Serfling E, Kämpgen E (January 2000). “Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells”. Blood. 95 (1): 277–85. PMID 10607713.
- Brasier AR, Lu M, Hai T, Lu Y, Boldogh I (August 2001). “NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence”. J. Biol. Chem. 276 (34): 32080–93. doi:10.1074/jbc.M102949200. PMID 11387332.
External links
External links
- FactorBook BCL3
- Human BCL3 genome location and BCL3 gene details page in the UCSC Genome Browser.